BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26506885)

  • 1. GNAS and KRAS mutational analyses of intraductal papillary neoplasms of the pancreas and bile duct developing in the same individual: A case report.
    Date K; Ohtsuka T; Fujimoto T; Gotoh Y; Nakashima Y; Kimura H; Matsunaga T; Mori Y; Mochidome N; Miyazaki T; Oda Y; Tanaka M; Nakamura M
    Pancreatology; 2015; 15(6):713-6. PubMed ID: 26506885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
    Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
    Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas.
    Tampakis A; Tampaki EC; Posabella A; Zettl A; Kouraklis G; von Flüe M; Guenin MO
    Pancreas; 2017 Jan; 46(1):e5-e7. PubMed ID: 27977634
    [No Abstract]   [Full Text] [Related]  

  • 4. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
    Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
    Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
    Sasaki M; Matsubara T; Nitta T; Sato Y; Nakanuma Y
    PLoS One; 2013; 8(12):e81706. PubMed ID: 24312577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
    Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
    Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GNAS Is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct.
    Tsai JH; Yuan RH; Chen YL; Liau JY; Jeng YM
    Am J Surg Pathol; 2013 Dec; 37(12):1862-70. PubMed ID: 24061513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas.
    Matsuzaka S; Karasaki H; Ono Y; Ogata M; Oikawa K; Tamakawa S; Chiba S; Muraki M; Yokochi T; Funakoshi H; Kono T; Nagashima K; Mizukami Y
    Pancreas; 2016 Jul; 45(6):915-8. PubMed ID: 27295533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of ectopic pancreas of the stomach accompanied by intraductal papillary mucinous neoplasm with GNAS mutation.
    Nambu N; Yamasaki T; Nakagomi N; Kumamoto T; Nakamura T; Tamura A; Tomita T; Miwa H; Shinohara H; Hirota S
    World J Surg Oncol; 2021 Oct; 19(1):309. PubMed ID: 34674710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?
    Rocha FG; Lee H; Katabi N; DeMatteo RP; Fong Y; D'Angelica MI; Allen PJ; Klimstra DS; Jarnagin WR
    Hepatology; 2012 Oct; 56(4):1352-60. PubMed ID: 22504729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.
    Matthaei H; Wu J; Dal Molin M; Debeljak M; Lingohr P; Katabi N; Klimstra DS; Adsay NV; Eshleman JR; Schulick RD; Kinzler KW; Vogelstein B; Hruban RH; Maitra A
    HPB (Oxford); 2012 Oct; 14(10):677-83. PubMed ID: 22954004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Date K; Ohtsuka T; Fujimoto T; Tamura K; Kimura H; Matsunaga T; Mochidome N; Miyazaki T; Mori Y; Oda Y; Nakamura M; Tanaka M
    Ann Surg; 2017 May; 265(5):969-977. PubMed ID: 28398963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synchronous malignant intraductal papillary mucinous neoplasms of the bile duct and pancreas requiring left hepatectomy and total pancreatectomy].
    Moon DB; Lee SG; Jung DH; Park GC; Park YH; Park HW; Kim MH; Lee SK; Yu ES; Kim JH
    Korean J Gastroenterol; 2014 Feb; 63(2):129-33. PubMed ID: 24561701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.